Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS: PVCT · Delayed Price · USD
0.198
-0.001 (-0.55%)
Apr 30, 2024, 3:58 PM EDT - Market closed
PVCT Revenue
In the year 2023, Provectus Biopharmaceuticals had annual revenue of $557.71K, a decrease of -43.61%. Revenue in the quarter ending December 31, 2023 was $121.11K, a -26.53% decrease year-over-year.
Revenue (ttm)
$557.71K
Revenue Growth
-43.61%
P/S Ratio
148.86
Revenue / Employee
$139,428
Employees
4
Market Cap
83.02M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 557.71K | -431.33K | -43.61% |
Dec 31, 2022 | 989.04K | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 4.18M | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 9.76B | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 0 | - | - |
Dec 31, 2006 | 1.37K | -5.17K | -79.07% |
Dec 31, 2005 | 6.54K | -25.32K | -79.48% |
Dec 31, 2004 | 31.85K | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 0 | - | - |
Dec 31, 2001 | 0 | - | - |
Dec 31, 2000 | 1.00 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
PVCT News
- 7 weeks ago - Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines - GlobeNewsWire
- 7 weeks ago - Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting - GlobeNewsWire
- 2 months ago - Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call - GlobeNewsWire
- 2 months ago - Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services - GlobeNewsWire
- 4 months ago - Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant - GlobeNewsWire
- 5 months ago - Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma - GlobeNewsWire
- 6 months ago - Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma - GlobeNewsWire